Orion Corp (ORNBV):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Orion Corp (ORNBV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9914
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:83
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フィンランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Orion Corp (Orion) is a developer of pharmaceuticals and diagnostic tests. The company develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients (APIs) and diagnostic tests. It focuses on developing pharmaceutical products for central nervous system disorders, cancer and respiratory. Orion’s client base consists of healthcare service providers and professionals, such as doctors, pharmacies, veterinarians, hospitals, healthcare centers, clinics and laboratories. The company sells its products in European markets through own human pharmaceuticals sales organization; and in international markets through several collaboration partners. It operates all manufacturing plants and most of its R&D facilities in Finland. Orion is headquartered in Espoo, Finland.

Orion Corp (ORNBV) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Orion Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Orion Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Orion Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Orion Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Orion Corp, Medical Devices Deals, 2012 to YTD 2018 10
Orion Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Orion Corp, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Orion and Amgen Enter into Marketing Agreement 12
Orion to Partner with Wisconsin Technology Innovation Initiative 13
Immunscape Enters into Research Collaboration with Orion 14
Orion Enters into Co-Marketing Agreement with A. Menarini Industrie Farmaceutiche Riunite 15
Orion Enters into Agreement with Asahi Kasei Pharma 16
Orion Enters into Co-Development Agreement with Helsinki University 17
Orion Enters into Agreement with Bayer for Prostate Cancer Treatment 18
Jubilant Biosys Enters Into Drug Discovery Agreement With Orion 19
Orion Enters Into R&D Agreement With Gedeon Richter For Cognitive Disorders 20
Licensing Agreements 21
Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 21
Orion Enters Into Licensing Agreement With Janssen Pharma 22
Orion Enters into License Agreement with Phyxius Pharma 23
A. Menarini Industrie Farmaceutiche Riunite Enters into Licensing Agreement with Orion 24
Orion And Hospira Extend Licensing Agreement For Precedex 25
Mylan Enters Into Licensing Agreement With Orion for Stalevo 26
Orion Enters Into Licensing Agreement With ProStrakan For Fareston 27
Debt Offering 28
Orion Announces Public Offering Of Bond Due 2019 For US$193 Million 28
Orion Corp – Key Competitors 29
Orion Corp – Key Employees 30
Orion Corp – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 33
Financial Announcements 33
Jul 18, 2018: Orion: Half-year financial report January-June 2018 33
Feb 07, 2018: Orion Group Financial Statement Release for 2017 46
Jul 19, 2017: Orion Group Half-Year Financial Report January-June 2017 53
Apr 26, 2017: Orion Group Interim Report January–March 2017 62
Feb 08, 2017: Orion Group Financial Statement Release for 2016 63
Corporate Communications 66
Sep 19, 2018: Changes in responsibility areas of the Orion Group executive management board 66
Feb 13, 2017: Change in Orion Group Executive Management Board as of 21 February 2017 67
Jan 27, 2017: Reijo Salonen, Senior Vice President, Pharmaceutical R&D, is CTO of the Year 2017 68
Government and Public Interest 69
Nov 01, 2018: Orion Research Foundation grants million euros for research in 2019 69
Feb 10, 2017: Orion Research Foundation grants EUR 1 million for research 71
Product News 72
12/20/2017: Alpha 2 agonizing sedative agent Pressedex Intravenous solution 200 µg Pfizer applies for adaptation to children 72
06/29/2018: CHMP announces recommendations on extensions of therapeutic indication for Dexdor 73
04/05/2017: Tenax Therapeutics Announces Review of Strategic Alternatives and Business Update 74
03/19/2017: Use of levosimendan with heart-lung machine fails to improve outcomes 75
Clinical Trials 76
Sep 01, 2017: Bayer to Present Abstract on Darolutamide at ESMO 2017 Congress 76
May 16, 2017: Tenax Meets with FDA to Discuss Positive Mortality Data and Potential Levosimendan NDA Submission 77
Jan 31, 2017: Tenax Therapeutics Announces Top-Line Results From Phase 3 LEVO-CTS Trial in Cardiac Surgery 78
Other Significant Developments 79
Sep 17, 2018: Creation of novel medicines and better patient care for the future in an ecosystem 79
Jun 14, 2018: Fermion’s new plant operational in Hanko-nearly 100% of production is exported 80
Feb 28, 2018: Orion’s Statutory Co-operation Negotiations Completed 81
Jan 04, 2018: Orion to renew operating model of its laboratories 82
Appendix 83
Methodology 83
About GlobalData 83
Contact Us 83
Disclaimer 83

List of Tables
Orion Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Orion Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Orion Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Orion Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Orion Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Orion Corp, Medical Devices Deals, 2012 to YTD 2018 10
Orion Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Orion and Amgen Enter into Marketing Agreement 12
Orion to Partner with Wisconsin Technology Innovation Initiative 13
Immunscape Enters into Research Collaboration with Orion 14
Orion Enters into Co-Marketing Agreement with A. Menarini Industrie Farmaceutiche Riunite 15
Orion Enters into Agreement with Asahi Kasei Pharma 16
Orion Enters into Co-Development Agreement with Helsinki University 17
Orion Enters into Agreement with Bayer for Prostate Cancer Treatment 18
Jubilant Biosys Enters Into Drug Discovery Agreement With Orion 19
Orion Enters Into R&D Agreement With Gedeon Richter For Cognitive Disorders 20
Aurigene and Orion Enter into Research and Option Agreement for Epigenetics Program 21
Orion Enters Into Licensing Agreement With Janssen Pharma 22
Orion Enters into License Agreement with Phyxius Pharma 23
A. Menarini Industrie Farmaceutiche Riunite Enters into Licensing Agreement with Orion 24
Orion And Hospira Extend Licensing Agreement For Precedex 25
Mylan Enters Into Licensing Agreement With Orion for Stalevo 26
Orion Enters Into Licensing Agreement With ProStrakan For Fareston 27
Orion Announces Public Offering Of Bond Due 2019 For US$193 Million 28
Orion Corp, Key Competitors 29
Orion Corp, Key Employees 30
Orion Corp, Subsidiaries 31

List of Figures
Orion Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Orion Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Orion Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Orion Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Orion Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Orion Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Orion Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Orion Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Orion Corp, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Orion Corp (ORNBV):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Rhizen Pharmaceuticals SA-製薬・医療分野:企業M&A・提携分析
    Summary Rhizen Pharmaceuticals SA (Rhizen Pharma), a subsidiary of Alembic Pharmaceuticals Ltd is a biopharmaceutical company that discovers and develops small molecule drugs. The company’s research products includes c-Met inhibitors, selective P13K inhibitors, CRAC channel inhibitors and GPR 119 ag …
  • AMAG Pharmaceuticals Inc (AMAG)-製薬・医療分野:企業M&A・提携分析
    Summary AMAG Pharmaceuticals Inc (AMAG) is a biopharmaceutical company that develops and commercializes specialty pharmaceutical products. The company focuses on maternal health, anemia management and cancer supportive care. Its major products include Makena (hydroxyprogesterone caproate injection) …
  • W. R. Grace & Co:企業の戦略・SWOT・財務分析
    W. R. Grace & Co - Strategy, SWOT and Corporate Finance Report Summary W. R. Grace & Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Zenotech Laboratories Ltd (532039):企業の財務・戦略的SWOT分析
    Zenotech Laboratories Ltd (532039) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Siemens Healthineers AG (SHL):企業の財務・戦略的SWOT分析
    Siemens Healthineers AG (SHL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • TriGranit Corporation:企業の戦略・SWOT・財務情報
    TriGranit Corporation - Strategy, SWOT and Corporate Finance Report Summary TriGranit Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Just Eat plc:企業の戦略・SWOT・財務情報
    Just Eat plc - Strategy, SWOT and Corporate Finance Report Summary Just Eat plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Aeterna Zentaris Inc (AEZS):医療機器:M&Aディール及び事業提携情報
    Summary Aeterna Zentaris Inc (Aeterna Zentaris) is a specialty biopharmaceutical company that focuses on the development and commercialization of novel pharmaceutical therapies for the treatment of endocrine disorders. The company’s lead product, macimorelin, a ghrelin receptor agonist and orally-ac …
  • Misonix Inc (MSON):医療機器:M&Aディール及び事業提携情報
    Summary Misonix Inc (Misonix) is a medical technology company that provides ultrasonic surgical devices for neurosurgical, spinal, advanced wound care and general surgery procedures. The company’s major products include BoneScalpel and BoneScalpel MIS cutting system; SonaStar surgical aspirator; Son …
  • AstraZeneca Plc (AZN)-医療機器分野:企業M&A・提携分析
    Summary AstraZeneca plc (AstraZeneca) is a biopharmaceutical company that endeavors to discover, produce and commercialize a wide range of prescription drugs. It focuses on therapy areas such as respiratory; cardiovascular and metabolic disease (CVMD); and cancer, besides autoimmune, infection and n …
  • Zenotech Laboratories Ltd (532039):企業の財務・戦略的SWOT分析
    Zenotech Laboratories Ltd (532039) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Campofrio Food Group, S.A.:企業の戦略・SWOT・財務情報
    Campofrio Food Group, S.A. - Strategy, SWOT and Corporate Finance Report Summary Campofrio Food Group, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • HanAll Biopharma Co Ltd (009420):企業の財務・戦略的SWOT分析
    Summary HanAll Biopharma Co Ltd (HanAll), formerly HanAll Pharmaceutical Co Ltd, is a developer of generic and specialty drugs for treatment of diseases related to digestive, endocrine, musculoskeletal and urinary system. The company’s pipeline products include HL036, a drug being developed for trea …
  • Clinical Innovations LLC-医療機器分野:企業M&A・提携分析
    Summary Clinical Innovations LLC (Clinical Innovations), a subsidiary of Pritzker Group Company is a medical device company that offers healthcare products for women and infants. The company offers products such as safety heelsticks, traxi panniculus retractor, ROM plus membrane testing, tamponade s …
  • OGE Energy Corp (OGE):企業の財務・戦略的SWOT分析
    OGE Energy Corp (OGE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Hadera Paper Ltd.:企業の戦略・SWOT・財務情報
    Hadera Paper Ltd. - Strategy, SWOT and Corporate Finance Report Summary Hadera Paper Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Valeo S.A.:企業の戦略・SWOT・財務情報
    Valeo S.A. - Strategy, SWOT and Corporate Finance Report Summary Valeo S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Southern Maryland Electric Cooperative Inc:発電所・企業SWOT分析
    Southern Maryland Electric Cooperative Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, infor …
  • Seoul National University Hospital:製薬・医療:M&Aディール及び事業提携情報
    Summary Seoul National University Hospital (SNUH) is a healthcare service provider. It operates as the representative medical center of Korea. The hospital focuses on raising the standards of nation’s healthcare system, medical education, research and patient care. It offers services such as outpati …
  • OJSC Dixy Group:企業の戦略・SWOT・財務情報
    OJSC Dixy Group - Strategy, SWOT and Corporate Finance Report Summary OJSC Dixy Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆